Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α

Emilio Jirillo, Luigi Amati, Luigi Caradonna, Beatrice Greco, Raffaele Cozzolongo, Renato Cuppone, Giuseppina Piazzolla, Domenico Caccavo, Salvatore Antonaci, Onofrio G. Manghisi

Research output: Contribution to journalArticle

Abstract

CD14 is a monocyte/polymorphonuclear cell receptor for lipopolysaccharide (LPS)-LPS Binding Protein (LBP), which mediates most of the toxic effects exerted by such a bacterial component in the host. Here, we provide evidence that sCD14 and interferon (IFN)-γ serum levels are significantly higher in chronic hepatitis C (CH-C) patients than those detected in normal donors. On the other hand, CD4+/CD8+ antibacterial activity is depressed, thus facilitating entry of bacteria into the host. Of note, all these immune parameters are not modified by in vivo IFN-α administration over a period of one year. Finally, after 12 months of IFN-α treatment number of CH-C patients with detectable levels of plasmatic LPS increased, thus indicating a continuous release of LPS into the host and also suggesting a putative pathogenetic role for sCD14 LPS-LBP complex in subjects affected by CH-C virus infection.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalImmunopharmacology and Immunotoxicology
Volume20
Issue number1
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α'. Together they form a unique fingerprint.

  • Cite this

    Jirillo, E., Amati, L., Caradonna, L., Greco, B., Cozzolongo, R., Cuppone, R., Piazzolla, G., Caccavo, D., Antonaci, S., & Manghisi, O. G. (1998). Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α. Immunopharmacology and Immunotoxicology, 20(1), 1-14.